Overview of cAPPricorn-1 Trial of Mivelsiran Presented at CTAD Conference 2024

Overview of cAPPricorn-1 Trial of Mivelsiran Presented at CTAD Conference 2024

Trial design and rationale for the global Phase 2 cAPPricorn-1 study of mivelsiran (ALN-APP) in patients with cerebral amyloid angiopathy (CAA), were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024.

Lee, et al. “Design and Rationale of cAPPricorn-1, A Phase 2 Study of Mivelsiran in Patients with Cerebral Amyloid Angiopathy”